225Ac-PSMA-617/177Lu-PSMA-617串联治疗转移性去势抵抗性前列腺癌的初步经验
该回顾性初步研究分析20例对177Lu-PSMA-617单药治疗反应不足的晚期/终末期mCRPC患者,给予1个疗程低活度225Ac-PSMA-617联合全活度177Lu-PSMA-617串联治疗。结果显示65%患者最佳生化反应为PSA下降>50%,中位无进展生存19周、总生存48周,未出现3/4级口干。
要点
- 对177Lu-PSMA-617单药反应不足的mCRPC患者,串联治疗65%达PSA下降>50%。
- 低活度225Ac联合全活度177Lu的串联方案未出现3/4级口干,1级占40%、2级占25%。
- 中位无进展生存19周、总生存48周,提示该组合值得正式研究。
核心结论
- 对177Lu-PSMA-617单药治疗反应不足的晚期/终末期mCRPC患者,单疗程低活度225Ac-PSMA-617联合全活度177Lu-PSMA-617串联治疗可能安全增强PRLT疗效并减轻口干严重程度。
研究设计与样本
- 回顾性分析20例对177Lu-PSMA-617单药治疗反应不足后接受1个疗程225Ac-PSMA-617/177Lu-PSMA-617串联治疗的mCRPC患者。
主要发现
- 20例中13例(65%)最佳生化反应为PSA下降>50%。
- 中位无进展生存19周(95%CI 12–26),串联治疗给药后中位总生存48周(95%CI 4–92)。
- 口干1级8/20(40%)、2级5/20(25%)、3/4级0/20。
关键数值与推荐
- 225Ac-PSMA-617中位(最小-最大)给药活度为5.3(1.5–7.9)MBq,177Lu-PSMA-617为6.9(5.0–11.6)GBq。
- 串联治疗显著应答者以177Lu-PSMA-617单药维持,中位(最小-最大)1(0–5)个周期。
临床怎么用
- 对177Lu-PSMA-617单药反应不足的晚期mCRPC,可考虑低活度225Ac联合全活度177Lu的串联方案,但需正式研究验证。
局限性
- 为回顾性初步经验,样本仅20例,随访中位22周(范围14–63周),结论需正式研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter 225Ac showed promise against mCRPC but may cause severe and/or persistent xerostomia, which may substantially impair patients' quality-of-life. We hypothesized that when 177Lu-PSMA ligand alone is ineffective, tandem therapy with low-activity 225Ac-PSMA ligand plus full activity of the beta emitter may enhance efficacy while minimizing xerostomia severity. METHODS: We retrospectively analyzed pilot experience with 1 course of 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy in our first 20 patients with mCRPC receiving this intervention after insufficiently responding to 177Lu-PSMA-617 monotherapy. This cohort had late-stage/end-stage disease with high baseline prostate-specific antigen (PSA) concentration (median 215 ng/mL), heavy pre-treatment (abiraterone and/or enzalutamide, and 177Lu-PRLT [median cumulative activity, 26.3 GBq] in 20/20 patients, 100%; docetaxel and/or cabazitaxel in 13/20 patients, 65%), and frequent Eastern Cooperative Oncology Group performance status of 2 (8/20 patients, 40%). RESULTS: Median (minimum-maximum) administered activities were 225Ac-PSMA-617, 5.3 (1.5-7.9) MBq, and 177Lu-PSMA-617, 6.9 (5.0-11.6) GBq. Significant responders to tandem therapy received 177Lu-PSMA-617 monotherapy as maintenance (median [minimum-maximum]: 1 [0-5] cycle). After a median (minimum-maximum) 22 (14-63) weeks' follow-up, 13/20 patients (65%) had as best biochemical response a PSA decline > 50%. Median (95% confidence interval) progression-free survival was 19 (12-26) weeks, and overall survival was 48 (4-92) weeks post-tandem therapy administration. Xerostomia was reported as grade 1 (very mild) in 8/20 patients (40%), grade 2 (mild) in 5/20 (25%), and grade 3/4 in 0/20. CONCLUSIONS: Our results suggest that a single course of tandem therapy with low-activity 225Ac-PSMA-617/full-activity 177Lu-PSMA-617 may safely enhance response to PRLT in men with late-stage/end-stage mCRPC while minimizing xerostomia severity. Formal study of this combination is warranted.
引用
- Khreish F, Ebert N, Ries M, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2019. PMID: 31758224. doi:10.1007/s00259-019-04612-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。